Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- OPCH +10.7%, PBPB +10.1%, TXG +5.9%, BOOT +5.7%, ARQT +5.7%, FOLD +5.3%, WDFC +4.3%, NTRA +4%, LULU +3.5%, NUS +2.7%, NVCR +2.6%, AXSM +2.4%, EXAS +2.2%, MD +2.1%, AKA +2.1%
Select healthcare related names showing strength:
- HUM +5.4%, CVS +3.3%, UNH +2.8%,
Other news:
- SAGE +35.9% (confirms receipt of acquisition proposal from Biogen (BIIB))
- ITCI +35.7% (Johnson & Johnson (JNJ) to acquire Intra-Cellular Therapies for $132.00 per share in cash for a total equity value of approximately $14.6 billion)
- MOLN +26.4% (Outlines Clinical Expansion Plans and Strengthens Radiopharma Strategic Focus for 2025 at 43rd Annual J.P. Morgan Healthcare Conference)
- ENFN +12.4% (Clearwater Analytics to acquire Enfusion for about $1.5 billion with equal mix of cash and stock)
- HHH +10.1% (Pershing Square Holdco proposes merger with HHH where HHH would have the option of receiving more than a majority of their merger consideration in cash at $85.00/share)
- CRBU +9.1% (Initiates the CB-010 GALLOP Phase 1 Trial in Lupus and Provides Outlook for Multiple Clinical Datasets in 2025)
- BPMC +4.1% (Provides 2025 Outlook and Highlights Strategy for Continued Growth)
- FTEL +3.2% (files $150 mln mixed shelf securities offering)
- BNED +3.1% (files $100 mln mixed shelf securities offering)
- CWAN +1.7% (Clearwater Analytics to acquire Enfusion for about $1.5 billion with equal mix of cash and stock)
- OLMA +1.6% (entered into exchange agreements)
- TEVA +1.1% (Announces Collaboration to Commercialize Formycon's Biosimilar Candidate to Eylea)